Format

Send to

Choose Destination
Front Pharmacol. 2018 Jan 4;8:960. doi: 10.3389/fphar.2017.00960. eCollection 2017.

SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis.

Dai S1,2,3, Yan Y1,3, Xu Z1,3,4, Zeng S1,3, Qian L1,3, Huo L5, Li X5, Sun L6, Gong Z1,3.

Author information

1
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
2
School of Pharmaceutical Sciences, Central South University, Changsha, China.
3
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
4
Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
5
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
6
Center for Molecular Medicine, Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China.

Abstract

Resistance to temozolomide (TMZ), the standard chemotherapy agent for glioblastoma (GBM), poses a major clinical challenge to GBM prognosis. Understanding the mechanisms of TMZ resistance can help to identify novel drug targets and more effective therapies. Recent studies suggest that bioenergetic alterations of cancer cells play important roles in drug resistance. In our study, the altered metabolism of cancer cells was observed using a metabolic PCR array. We found that stearoyl-coenzyme A desaturase 1 (SCD1), a key rate-limiting enzyme for synthesis of monounsaturated fatty acids, was significantly upregulated in TMZ-resistant GBM cells compared to their parental counterparts. Overexpression of SCD1 promoted resistance to TMZ in parental GBM cells, whereas SCD1 downregulation by siRNA could re-sensitize TMZ-resistant cells in vitro. Combinational treatment of TMZ and an SCD1-specific inhibitor showed a combined inhibitory effect on TMZ-resistant glioma cells. We also observed that overexpression of SCD1 promoted Akt/GSK3β/β-catenin signaling, while silencing of SCD1 inhibited the signaling. The combination of an Akt activator with exogenous SCD1 or the combined inhibition of Akt and enforced expression of SCD1 resulted in the most significant changes of Akt signaling. Functionally, significantly lower viability and mobility rates were observed in TMZ-resistant cells when treated with Akt inhibitors and an SCD1 inhibitor simultaneously compared to when treated individually. In conclusion, our study identified SCD1 along with its functional pathway as a novel target in the development of TMZ resistance. SCD1 inhibition used alone or in combination with Akt inhibition could effectively overcome TMZ resistance in gliomas.

KEYWORDS:

Akt signaling; SCD1; glioblastomas; resistance; temozolomide

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center